Project Grant R43HL186922
- The National Heart, Lung, and Blood Institute awarded Innovative Design Labs Inc. $1,020,633 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate a mannequin product line that improves training in cardiopulmonary resuscitation (CPR) and automated external defibrillator (AED) interventions. The recipient will create mannequins representing diverse body types and populations at highest risk for out-of-hospital cardiac arrest, addressing a...
- The National Heart, Lung, and Blood Institute awarded Pulsentry, Inc. $309,198 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and prototype an automated detection system for cardiac tamponade using existing fingertip pulse oximeters. Pulsentry will develop machine learning algorithms that analyze pulse waveform perturbations to identify early signs of cardiac tamponade, a medical emergency caused by fluid or clot accumulation around the heart...
- The National Heart, Lung, and Blood Institute awarded $316,609 to Remplenish, Inc. on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a novel myofunctional nipple device for preventing obstructive sleep apnea in infants. The recipient will design and validate a low-risk, low-burden device that delivers myofunctional therapy—oropharyngeal exercises integrated into infant bottle feeding—as a non-invasive first-line treatment and preventive measure...
- The National Heart, Lung, and Blood Institute awarded Linshom Medical, Inc. $322,277 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct clinical evaluation of an alarm-activated detection system for early intervention of emerging respiratory decline using Linshom's FDA-cleared Continuous Predictive Respiratory Sensor (CPRS). The funding supports clinical development activities demonstrating the health economic value of the CPRS system, which...
- The National Heart, Lung, and Blood Institute awarded Respair, Inc. $305,218 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate AssuranceET, a novel pediatric endotracheal tube with an ultra-soft micro-baffle sealing mechanism designed to replace traditional inflatable balloon cuffs and reduce airway trauma and aspiration risk in mechanically ventilated children. AssuranceET uses thin, flexible disc-shaped micro-baffles that fold...
- The National Heart, Lung, and Blood Institute awarded $499,932 to Safebvm Corp. on September 17, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to integrate capnography sensing into the SOTAIR device for standardizing manual ventilation technique and improving patient outcomes. SOTAIR is a lightweight (14 grams), battery-free attachment device compatible with all commercially available bag-valve masks that employs flow-blocking and pressure-control mechanisms to...
- The National Heart, Lung, and Blood Institute awarded Minnesota Healthsolutions Corporation $329,537 on August 15, 2026, to develop a novel balloon angioplasty inflation device under the Cardiovascular Diseases Research program (CFDA 93.837). The recipient will design and evaluate a prototype inflation device intended to improve safety and efficacy during percutaneous balloon angioplasty by accounting for molecular composition and elasticity differences in arterial tissue. Current market devices...
- CPR Therapeutics Inc. received a $512,000 National Science Foundation Project Grant award under the NSF Technology, Innovation, and Partnerships program to develop an automated multimodal cardiopulmonary resuscitation system. The one-year award will support preclinical research and optimization studies using a swine model of cardiac arrest to design a next-generation proof-of-concept prototype. The system aims to improve outcomes for sudden cardiac arrest patients by integrating multiple...
- The National Heart, Lung, and Blood Institute awarded Voyageur Medtech, Corp. $314,344 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a novel sensor and audible alarming device that alerts caregivers when a tracheostomy tube has been obstructed or decannulated. The project addresses a critical clinical need in pediatric tracheostomy management. Approximately 100,000 patients receive tracheostomy procedures annually in the United States,...
- The National Heart, Lung, and Blood Institute awarded Inflo Medical Inc. $595,332 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to optimize its MOBYBOX extracorporeal membrane oxygenation (ECMO) platform for pediatric use. Inflo Medical is redesigning the MOBYBOX's gas exchanger and pulsatile displacement pump to reduce thrombogenicity and hemolysis in pediatric patients. The Phase I Small Business Innovation Research effort focuses on two complementary...
The National Heart, Lung, and Blood Institute awarded Resuscitation Innovations LLC $396,098 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and test an adjustable-pressure impedance threshold device for cardiac arrest resuscitation and post-resuscitation care. The recipient will refine the design of the Adjustable Pressure for Emergency Care (APEC) device, a dual-setting airway device with selectable cracking pressures of -6 and -12 centimeters of water that enable field adjustment between cardiac arrest resuscitation and spontaneous breathing recovery states. Bench testing will confirm performance specifications, pressure-flow characteristics, dead space volume, and durability. Hemodynamic and respiratory performance will be evaluated in a porcine model of cardiac arrest and post-return-of-spontaneous-circulation spontaneous breathing. The current FDA-cleared impedance threshold device (ResQPod) uses a fixed cracking pressure that limits adaptability across patient conditions. The APEC device addresses this limitation by allowing rapid, on-the-fly pressure adjustment: higher pressures (-10 to -16 centimeters of water) augment circulation during cardiopulmonary resuscitation, while lower settings (-6 centimeters of water) reduce breathing effort in recovering or hypotensive patients. This is a Phase I SBIR project. Performance will take place in Edina, Minnesota from August 10, 2026, through July 31, 2027. The assistance type is a Project Grant.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $396.1k | 8/11/26 |